Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesCardiologymedical mutual - ohio Camzyos Coverage & Prior Aut…
    Ask Trek AI about this page
    Currentmedical mutual - ohioPolicy N/A

    Camzyos (mavacamten) — Obstructive Hypertrophic Cardiomyopathy Coverage Criteria

    Customize your policy alerts

    Sign up for all medical mutual - ohio policy alerts

    Know when medical mutual - ohio releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines recommended prior authorization criteria, approval durations, prescribing clinician requirements, and conditions not recommended for approval for Camzyos (mavacamten) for adults with symptomatic obstructive hypertrophic cardiomyopathy.

    Policy Summary
    Payermedical mutual - ohio
    PolicyCamzyos (mavacamten) — Obstructive Hypertrophic Cardiomyopathy Coverage Criteria
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateMay 21, 2026
    Last ReviewMay 21, 2026
    Next Review DateMay 21, 2026
    Key ActionSubmit prior authorization with documentation that the patient is ≥18 years, NYHA II–III, meets LV wall thickness and LVOT gradient thresholds, has LVEF ≥55%, and is prescribed by a cardiologist.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥18minimum patient age
    NYHA II–IIIsymptom class required
    ≥30/≥50LVOT gradient
    ≥55%LVEF requirement
    1 yrapproval length

    Recommended Authorization Criteria

    Obstructive Hypertrophic Cardiomyopathy — Initial or Ongoing Therapy

    Coverage of Camzyos is recommended in those who meet the following criteria. Approve for 1 year.

    A or B

    • A) Initial Therapy

      • i: Patient is ≥ 18 years of age
      • ii: Patient has at least one symptom associated with obstructive hypertrophic cardiomyopathy AND has New York Heart Association (NYHA) Class II or III symptoms

        Examples of symptoms include shortness of breath, chest pain, lightheadedness, fainting, fatigue, and reduced ability to perform physical exercise.

      • iii: Left ventricular hypertrophy meets one: maximal LV wall thickness ≥15 mm OR familial HCM with maximal LV wall thickness ≥13 mm
      • iv: Peak left ventricular outflow tract (LVOT) gradient ≥30 mmHg at rest OR ≥50 mmHg after provocation (Valsalva maneuver or post-exercise)
      • v: Left ventricular ejection fraction ≥55%
      • vi: Either tried or currently receiving at least one beta-blocker OR a nondihydropyridine calcium channel blocker for ≥3 months, OR has a contraindication or intolerance to those agents3 months

        Examples of beta-blockers: metoprolol, atenolol, bisoprolol. Examples of nondihydropyridine CCBs: verapamil, diltiazem. Examples of contraindications/intolerances described in policy.

      • vii: Medication is prescribed by a cardiologist
    • B) Currently Receiving Camzyos

      • i: Patient has been established on therapy for at least 1 year

        Patients with <1 year of therapy or restarting are reviewed under Initial Therapy criteria.

      • ii: Patient is ≥ 18 years of age
      • iii: Currently or prior to starting therapy, patient has or had at least one symptom associated with obstructive hypertrophic cardiomyopathy AND was in NYHA Class II or III

        Examples of symptoms include shortness of breath, chest pain, lightheadedness, fainting, fatigue, and reduced ability to perform physical exercise.

      • iv: Patient experienced a beneficial clinical response by at least one objective measure OR experienced stabilization or improvement in at least one symptom related to obstructive HCM

        Objective measures examples: improved peak VO2, decreased LVOT gradient, reduced NT-proBNP, decreased high-sensitivity cardiac troponin I, reduced ventricular mass index, reduced left atrial volume index, improved KCCQ-23 or HCMSQ scores.

      • v: Medication is prescribed by a cardiologist
    ref

    Coverage is not recommended for circumstances that are not explicitly listed in the Recommended Authorization Criteria. This list of non‑recommended circumstances is not exhaustive and will be updated as new published data become available.

    Use of Camzyos (mavacamten) for indications other than those specified in the Recommended Authorization Criteria is not recommended and may be considered not medically necessary.

    Clinical Thresholds and Key Parameters

    inv-04: Left ventricular wall thickness — thresholds
    ThresholdMaximal left ventricular wall thickness ≥ 15 mm (general)
    Familial HCM exceptionIf familial hypertrophic cardiomyopathy, maximal LV wall thickness threshold ≥ 13 mm
    Source contextRequirement is part of initial therapy criteria for Camzyos coverage
    inv-05: Left ventricular outflow tract (LVOT) gradient
    Resting LVOT gradientPeak LVOT gradient ≥ 30 mmHg at rest
    Provoked LVOT gradientPeak LVOT gradient ≥ 50 mmHg after provocation (Valsalva maneuver or post-exercise)
    ContextThis hemodynamic threshold is required in the policy's initial therapy criteria for Camzyos
    inv-06: Left ventricular ejection fraction (LVEF)
    LVEF requirementLeft ventricular ejection fraction ≥ 55%
    PlacementSpecified as a mandatory criterion (v) for initial Camzyos coverage
    PurposeEnsures preserved systolic function before initiating therapy

    Prescriber, Documentation, and Authorization Requirements

    Prior Authorization

    Prior authorization and prescriber specialty

    Prior authorization is recommended for pharmacy benefit coverage of Camzyos. Initial approval requires the medication be prescribed by or in consultation with a physician who specializes in the condition being treated (cardiologist).

    • All approvals for initial therapy are provided for the initial approval duration noted (approve for 1 year).
    • Medication for initial therapy must be prescribed by a cardiologist or prescribed in consultation with a specialist.
    Step Therapy

    Trial of first-line agents (β-blocker or nondihydropyridine CCB ≥3 months)

    Before approval for initial therapy, the patient must have tried or be currently receiving at least one beta-blocker or a nondihydropyridine calcium channel blocker for at least 3 months, unless the prescriber documents a contraindication or intolerance.

    • Examples of beta-blockers: metoprolol, atenolol, bisoprolol.
    • Examples of nondihydropyridine calcium channel blockers: verapamil, diltiazem.
    • Examples of contraindications to beta-blockers: bradycardia, severe hypotension, severe reactive airway disease or active bronchospasm.
    • Examples of intolerances to beta-blockers: symptomatic fatigue or exercise intolerance, symptomatic bradycardia, hypotension.
    • Examples of contraindications to calcium channel blockers: bradycardia, hypotension.
    • Examples of intolerances to calcium channel blockers: peripheral edema, dizziness, orthostasis.
    Documentation Required

    Provide records and test results to support medical necessity

    The Company may request additional documentation to support medical necessity and requires that requested records be made available upon request.

    • Documentation that may be requested includes patient records, test results, and credentials of the provider ordering or performing the service.
    • Additional documentation supporting medical necessity must be made available upon request to the Company.
    Denial Risk

    Denial triggers for reimbursement

    The Company may deny reimbursement if the drug or services were not medically necessary, were investigational/experimental, were not within the member's benefits, or if a pattern of billing or practice is inappropriate or excessive.

    • Denial may occur for services determined to be not medically necessary, investigational/experimental, or outside the scope of member benefits.
    • Denial may occur if a pattern of billing or other practice is found to be inappropriate or excessive.

    Drug and Disease Background

    Camzyos (mavacamten) is a cardiac myosin inhibitor indicated to improve functional capacity and symptoms in adults with symptomatic obstructive hypertrophic cardiomyopathy. Clinical efficacy has been established for patients with symptomatic, obstructive HCM (typically NYHA Class II–III), and treatment and monitoring are generally managed by cardiology specialists given safety and long‑term efficacy considerations.

    Key Definitions

    inv-12: Obstructive hypertrophic cardiomyopathy — definition and example symptoms
    DefinitionHypertrophic cardiomyopathy with left ventricular outflow tract obstruction and symptomatic disease
    Example symptomsShortness of breath (dyspnea), chest pain, lightheadedness, fainting (syncope), fatigue, and reduced exercise capacity
    Functional class requirementPatient typically has NYHA Class II or III symptoms as specified in the coverage criteria
    Policy Summary
    Payermedical mutual - ohio
    PolicyCamzyos (mavacamten) — Obstructive Hypertrophic Cardiomyopathy Coverage Criteria
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateMay 21, 2026
    Last ReviewMay 21, 2026
    Next Review DateMay 21, 2026
    Key ActionSubmit prior authorization with documentation that the patient is ≥18 years, NYHA II–III, meets LV wall thickness and LVOT gradient thresholds, has LVEF ≥55%, and is prescribed by a cardiologist.
    SourceLink
    On This Page
    Recommended Authorization CriteriaClinical Thresholds and Key ParametersPrescriber, Documentation, and Authorization RequirementsDrug and Disease BackgroundKey Definitions

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.